Attias D
Pediatric Hemotology/Oncology Unit, Bnai Zion Medical Center, Technion, Israel.
J Pediatr Hematol Oncol. 1995 Feb;17(1):13-8. doi: 10.1097/00043426-199502000-00002.
Increased understanding of the pathophysiology of anemia of prematurity (AOP) has emerged over the past years. It is apparent that low levels of endogenous erythropoietin (Epo) is the basis for this phenomenon. This has resulted in an effective therapeutic approach for this condition. Administration of Epo can ameliorate the signs and symptoms of AOP and lessen, and in many cases avoid, the necessity for blood transfusion.
在过去几年里,人们对早产儿贫血(AOP)的病理生理学有了更多的了解。显然,内源性促红细胞生成素(Epo)水平低是这一现象的基础。这就产生了一种针对这种情况的有效治疗方法。给予促红细胞生成素可以改善早产儿贫血的体征和症状,并减少,而且在许多情况下避免输血的必要性。